Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis.
- Author:
Yang LI
1
;
Lin Quan TANG
;
Li Ting LIU
;
Shan Shan GUO
;
Yu Jing LIANG
;
Xue Song SUN
;
Qing Nan TANG
;
Jin Xin BEI
;
Jing TAN
;
Shuai CHEN
;
Jun MA
;
Chong ZHAO
;
Qiu Yan CHEN
;
Hai Qiang MAI
Author Information
- Publication Type:Original Article
- Keywords: Nasopharyngeal carcinoma; Children and adolescents; Chemoradiotherapy; Induction chemotherapy; Survival
- MeSH: Adolescent*; Chemoradiotherapy*; Child*; Cohort Studies*; Disease-Free Survival; Follow-Up Studies; Humans; Induction Chemotherapy*; Methods; Neutropenia; Radiotherapy
- From:Cancer Research and Treatment 2018;50(4):1304-1315
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: The purpose of this study was to evaluate the long-term clinical outcome and toxicity of induction chemotherapy (IC) followed by concomitant chemoradiotherapy (CCRT) compared with CCRT alone for the treatment of children and adolescent locoregionally advanced nasopharyngeal carcinoma (LACANPC). MATERIALS AND METHODS: A total of 194 locoregionally advanced nasopharyngeal carcinoma patients youngerthan 21 years who received CCRT with or without IC before were included in the study population. Overall survival (OS) rate, progression-free survival (PFS) rate, locoregional recurrence-free survival (LRFS) rate, and distant metastasis-free survival (DMFS) rate were assessed by the Kaplan-Meier method and a log-rank test. Treatment toxicities were clarified and compared between two groups. RESULTS: One hundred and thiry of 194 patients received IC+CCRT. Patients who were younger and with more advanced TNM stage were more likely to receive IC+CCRT and intensive modulated radiotherapy. The addition of IC before CCRT failed to improve survival significantly. The matched analysis identified 43 well-balanced patients in both two groups. With a median follow-up of 51.5 months, no differences were found between the IC+CCRT group and the CCRT group in 5-year OS (83.7% vs. 74.6%, p=0.153), PFS (79.2% vs. 73.4%, p=0.355), LRFS (97.7% vs. 88.2%, p=0.083), and DMFS (81.6% vs. 81.6%, p=0.860). N3 was an independent prognostic factor predicting poorer OS, PFS, and DMFS. The addition of IC was associated with increased rates of grade 3 to 4 neutropenia. CONCLUSION: This study failed to demonstrate that adding IC before CCRT could provide a significant additional survival benefit for LACANPC patients. Further investigations are warranted.
